(Q42774672)

24 May 2018

title

Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis (English)

1 reference

24 May 2018

0 references

Kenneth L McClain

14

0 references

Miriam Merad

13

object named as

Miriam Merad

1 reference

24 May 2018

author name string

Rikhia Chakraborty

1

1 reference

24 May 2018

Thomas M Burke

2

1 reference

24 May 2018

Oliver A Hampton

3

1 reference

24 May 2018

Daniel J Zinn

4

1 reference

24 May 2018

Karen Phaik Har Lim

5

1 reference

24 May 2018

Harshal Abhyankar

6

1 reference

24 May 2018

Brooks Scull

7

1 reference

24 May 2018

Vijetha Kumar

8

1 reference

24 May 2018

Nipun Kakkar

9

1 reference

24 May 2018

David A Wheeler

10

1 reference

24 May 2018

Angshumoy Roy

11

1 reference

24 May 2018

Poulikos I Poulikakos

12

1 reference

24 May 2018

D Williams Parsons

15

1 reference

24 May 2018

Carl E Allen

16

1 reference

24 May 2018

language of work or name

English

0 references

publication date

11 October 2016

1 reference

24 May 2018

published in

Blood

1 reference

24 May 2018

volume

128

1 reference

24 May 2018

issue

21

1 reference

24 May 2018

page(s)

2533-2537

1 reference

24 May 2018

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

RAF inhibitors that evade paradoxical MAPK pathway activation

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Genomic Alterations in Langerhans Cell Histiocytosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Pilocytic astrocytoma: pathology, molecular mechanisms and markers.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Somatic activating ARAF mutations in Langerhans cell histiocytosis.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Improved survival with MEK inhibition in BRAF-mutated melanoma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

The structural basis for control of eukaryotic protein kinases

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Genomic complexity and AKT dependence in serous ovarian cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Recurrent BRAF mutations in Langerhans cell histiocytosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5123197

10.1182/BLOOD-2016-08-733790

16 August 2018

Identifiers

DOI

1 reference

24 May 2018

PMC publication ID

5123197

1 reference

24 May 2018

PubMed publication ID

27729324

1 reference

24 May 2018